Novartis (Basel, CH / East Hanover, NJ) sponsors 492 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 179 active protocols (80 recruiting now), 194 completed protocols, and 224 all-time original FDA Drugs@FDA NDA and BLA approvals.